Objective-Angiotensin II (Ang II) is implicated in processes underlying the development of arterial wall remodeling events, including cellular hypertrophy and inflammation. We previously documented the activation of IκB kinase-β (IKKβ) in Ang II-treated cells, a kinase involved in inflammatory reactions. In light of a study suggesting a role of IKKβ in angiogenesis through its effect on the tuberous sclerosis (TSC)1/2-mammalian target of rapamycin complex 1 pathway in cancer cells, we hypothesized that targeting IKKβ could reduce arterial remodeling events by affecting both the inflammatory and the growth-promoting response of Ang II. Approach and Results-Treatment of aortic vascular smooth muscle cells with Ang II induced the rapid and sustained phosphorylation of TSC1 on Ser511, which paralleled the activation of effectors of the mammalian target of rapamycin complex 1 pathway. Furthermore, we show that Ser511 of TSC1 acted as a phosphoacceptor site for Ang II-activated IKKβ. Consistent with this, the use of different short hairpin RNA constructs targeting IKKβ reduced Ang II-induced TSC1, S6 kinase, and eukaryotic translation initiation factor 4E-binding protein 1 phosphorylation and the rate of protein synthesis. Overexpression of TSC1 lacking Ser511 in vascular smooth muscle cells also exerted detrimental effects on the hypertrophic effect of Ang II. Furthermore, the selective IKKβ inhibitor N-(6-chloro-7-methoxy-9H-β-carbolin-8yl)-2 methylnicotinamide reduced the inflammatory response and dose-dependently diminished Ang II-induced TSC1 phosphorylation and effectors of the mammalian target of rapamycin complex 1 pathway, leading to inhibition of protein synthesis in vitro and in rat arteries in vivo.
A s the effector of the renin-angiotensin system, the hormone angiotensin II (Ang II) plays a critical role in controlling cardiovascular homeostasis. By binding to the Ang II receptor (Ang II type I receptor or Ang II type II receptor), it regulates salt/water homeostasis and vasoconstriction and modulates cellular responses in a paracrine and autocrine manner. However, deregulated production of Ang II in the vessel wall has been implicated in cardiovascular diseases associated with vascular smooth muscle cell (VSMC) hypertrophy and inflammation, including hypertension and atherosclerosis. [1] [2] [3] [4] We and others have shown that this inflammatory response mediated by Ang II, involving nuclear factor-κB (NF-κB) transcription factors, required activation of IκB kinase-β (IKKβ) in VSMC. [5] [6] [7] In the classical NF-κB pathway, IKKβ forms the IκB kinase (IKK) complex with IKKα and the scaffold protein NF-κB essential modulator. In this complex, the IKKβ subunit can modulate the activity of the NF-κB pathway by phosphorylating IκBα at Ser32 and Ser36, which leads to its polyubiquitination and degradation, resulting in release and nuclear accumulation of NF-κB to induce gene expression. 8 Interestingly, in addition to IκBα, many other substrates of IKKβ have been identified, including β-catenin, 9 p65, 6 steroid receptor coactivator protein 3, 10 forkhead O transcription factor 3α, 11 cylindromatosis (turban tumor syndrome), 12 docking protein 1, 13 and, more recently, tuberous sclerosis (TSC) 1. 14 The tumor suppressor gene TSC1 (hamartin) acts in a complex with TSC2 (tuberin) and prevents its ubiquitination and degradation. 15 The hamartin-tuberin complex suppresses the activation of the small GTPase Ras homolog enriched in brain (RHEB) via a GTPase-activating domain near the C terminus of tuberin. 16 Active GTP-bound RHEB activates the mammalian target of rapamycin complex 1 (mTORC1), which results in phosphorylation of eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) and S6 kinases (S6K1 and S6K2), 17 to increase protein translation and cell growth. Hence, when functional hamartin or tuberin is lost, increased levels of active RHEB constitutively activate mTORC1, which in turn leads to increased cell growth.
Diverse environmental cues, including growth factors, energy status, oxygen, and amino acids, promote mTORC1 signaling. Particularly in response to growth factors (eg, insulin, insulin-like growth factor 1, and epidermal growth factor), TSC2 is phosphorylated by several kinases, including V-Akt murine thymoma viral oncogene homolog (AKT) (on Ser939, Ser981, and Thr1462), extracellular signal-regulated kinases (ERK; on Ser664), and p90 ribosomal S6 kinase (on Ser1798), which leads to inhibition of the GTPase-activating protein function of TSC2 toward RHEB. 18, 19 Conversely, AMP-activated protein kinase and glycogen synthase kinase-3 phosphorylation of TSC2 (on Ser1345 and Ser1341 plus Ser1337, respectively) positively regulates its GTPaseactivating protein function toward RHEB. 20 Interestingly, in cancer cells activated IKKβ was demonstrated to phosphorylate TSC1 on Ser511, which results in the inhibition of the TSC1-TSC2 complex and, consequently, the activation of mTORC1, leading to inflammation-mediated tumor angiogenesis. 14 In addition to mediating vascular inflammation, 3, 5 Ang II also acts as a growth factor that stimulates protein synthesis and induces cellular hypertrophy in VSMC. 21 Through the Ang II type I receptor, Ang II induces phosphorylation of tyrosine kinases, including V-src avian sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog, Janus family kinases, focal adhesion kinase, proline-rich tyrosine kinase 2, and phosphatidylinositol 3-kinase to stimulate cell growth. 22, 23 In addition, Ang II activates mitogen-activated protein kinases, including ERK1/2 and mTOR, which are both involved in the growth properties of the peptide. 21, 24 Despite these investigations, the molecular mechanisms by which Ang II mediates VSMC growth are not fully elucidated. We, therefore, hypothesized that Ang II-activated IKKβ is not only involved in the inflammatory response but is also involved in the signal transduction underlying the hypertrophic response. Thus, the present study was undertaken to examine this possible new role of IKKβ in the phenotypic responses of VSMC.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Ang II Induces the Phosphorylation of TSC1 at Ser511, Which Parallels the Activation of mTORC1 Effectors
We first interrogated whether Ang II had the ability to induce the phosphorylation of TSC1 on Ser511, a proposed IKKβ consensus site. 14 Using primary human aortic VSMC exposed to Ang II, we detected a significant increase in the Ser511 phospho-signal ( Figure 1A and 1B). This signal occurred rapidly, was sustained, and, importantly, correlated with the presence of the mTOR Ser2481 phospho-signal, which directly monitors intrinsic mTORC-specific catalytic activity. 25 We, therefore, investigated whether the observed increase in the phosphorylation of TSC1 at Ser511 and mTOR activation correlated with the activation of mTORC1 effectors, namely S6K1 and 4E-BP1. As previously reported, 26, 27 an increase in the phospho-signal of S6K1 at Thr389 (pS6K1(T389)) and 4E-BP1 at Ser65 (p4E-BP1(S65)) on addition of Ang II was observed ( Figure 1C and 1D). Interestingly, these perfectly paralleled phosphorylation of TSC1 at Ser511. Similar results were obtained in quiescent rat aortic smooth muscle cells stimulated with Ang II (not shown). Altogether, these results suggest a possible role of IKKβ in the control of effectors controlling the translational machinery. 
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IKKβ Is Required for the Phosphorylation of TSC1 on Ser511 and Activation of mTORC1 Effectors in Ang II-treated VSMC
We have previously demonstrated that Ang II induces a rapid and sustained activation of IKKβ in primary VSMC. 5 Consequently, we assessed its phosphotransferase activity toward recombinant TSC1 using an in vitro kinase assay. We observed that IKKβ strongly phosphorylated TSC1 on Ang II activation. This phosphorylation signal was similar in intensity to that of IκBα, the canonical substrate of IKKβ. Interestingly, IKKβ was no longer able to induce the phosphorylation of TSC1 when the IKKβ consensus site (Ser511) was mutated to an alanine residue (Figure 2A and 2B). Next, we examined the requirement of IKKβ in the Ang II-induced phosphorylation of TSC1 and mTORC1 effectors in primary cultured human VSMC. Reducing the expression level of IKKβ with 2 different short hairpin RNA constructs significantly affected the ability of Ang II to induce the phosphorylation of TSC1 at Ser511 and the phosphorylation of S6K1 and 4E-BP1 ( Figure 2C and 2D). Taken together, these results demonstrate the requirement of IKKβ in the phosphorylation of TSC1 at Ser511 and the activation of the mTORC1 pathway in response to Ang II.
Inhibition of Ang II-Induced Activation of the mTORC1 Pathway by ML120B
In addition to the short hairpin RNA knockdown approach, we used a pharmacological approach. N-(6-chloro-7-methoxy-9Hβ-carbolin-8-yl)-2 methylnicotinamide (ML120B) is a potent and selective ATP-competitive inhibitor of IKKβ. ML120B has been reported to inhibit tumor necrosis factor α-induced nuclear translocation of p65 and inhibit the growth of multiple myeloma cells in vitro and in vivo. 28, 29 ML120B was also shown to inhibit lipopolysaccharide-induced tumor necrosis factor α production in vivo and reduce inflammation and bone destruction in a rodent model of arthritis. 30, 31 In our hands, this inhibitor was potent in inhibiting NF-κB activation because it antagonized tumor necrosis factor α-induced IκBα degradation, with maximal efficacy occurring at 30 µmol/L in human aortic VSMC ( Figure IA in the online-only Data Supplement). Importantly, this concentration also blunts the ability of Ang II to induce the expression of the inflammatory marker vascular cell adhesion molecule 1 (VCAM-1) in cultured VSMC ( Figure IB in the online-only Data Supplement). This inhibitor was next used to investigate the involvement of IKKβ in Ang II-induced hypertrophy. Quiescent human aortic VSMC were incubated with ML120B added at a dose range of 3 to 70 µmol/L before stimulating with Ang II. Interestingly, inhibition of IKKβ with increased amounts of ML120B correlated with a reduction in Ang II-induced phosphorylation of TSC1 on Ser511 and the autophosphorylation of mTOR and phosphorylation of the downstream mTORC1 effectors S6K1 and 4E-BP1 ( Figure 3 ). Similar results were obtained in rat aortic VSMC stimulated with Ang II ( Figure IIA in the online-only Data Supplement). The effect of the specific IKKβ inhibitor was also tested on Ang II stimulation during a time course. Pretreatment with 30 µmol/L ML120B compromised the ability of Ang II to activate S6K1 and inhibit 4E-BP1 at all time points examined, whereas Ang II-induced ERK1/2 phosphorylation (pERK1/2(T185/Y187)) was not ( Figure IIB in the online-only Data Supplement). Thus, the kinase activity of IKKβ is required for Ang II to stimulate effectors of the translational machinery.
IKKβ-TSC1 Signaling Cascade Is Required for the Hypertrophic Effect of Ang II in VSMC
We next addressed the role of IKKβ and TSC1 in the ability of Ang II to increase the rate of protein synthesis in cultured VSMC. Importantly, use of the IKKβ inhibitor ML120B was found to concentration-dependently inhibit Ang II-induced protein synthesis with an IC50 of 10.6 µmol/L ( Figure 4A ). It is noteworthy that this concentration also abolished ≈50% of the quantified TSC1 and S6K1 phosphorylation ( Figure 3B and 3D). Consistent with the effect of the pharmacological inhibitor, reduction in the expression level of IKKβ with distinct short hairpin RNA constructs in quiescent primary human VSMC inhibited Ang II-induced protein synthesis ( Figure 4B ). Same observation was made in rat VSMC exposed to 2 different siRNA duplexes targeting IKKβ (data not shown). Remarkably, this remodeling event is likely under the specific control of IKKβ over the growth suppressor gene TSC1. Although transient overexpression of TSC1wt had only marginal effect on the ability of Ang II to induce [ 3 H]-leucine incorporation, the use of a mutant form of TSC1 (S511A) lacking the IKKβ consensus site (and, therefore, not phosphorylated by IKKβ; see Figure 2A ) severely compromised the hypertrophic effect of Ang II ( Figure 4C ). However, expression of the NF-κB super-repressor (IκBα-2Ndelta4) 32 in VSMC, which was previously shown by our group to abrogate Ang II-induced NF-κB activation and expression of chemokine (C-C motif) ligand 2 and interleukin-6, 6 did not alter the trophic effect of the peptide ( Figure III in the online-only Data Supplement). Taken together, our results demonstrate that both the kinase activity of IKKβ and the phosphorylation of TSC1 at Ser511 are required for the activation of effectors of the translational machinery and the hypertrophic effect of Ang II.
Additive Effect of ML120B and UO126 on Ang II-Stimulated Protein Synthesis
We have previously shown that activation of the mitogenactivated protein kinase kinase (MEK)1/2-ERK1/2 pathway is necessary but not sufficient for the hypertrophic effects of Ang II in VSMC. 21 Accordingly, the relative contribution of the ERK1/2 pathway and IKKβ to the regulation of protein synthesis was next examined. Simultaneous treatment of quiescent VSMC with ML120B and MEK1/2 inhibitor UO126 had an additive effect on the inhibition of Ang II-induced protein synthesis compared with the effect of each drug alone ( Figure  IV in the online-only Data Supplement). These results suggest that ERK1/2 and IKKβ act via distinct pathways to increase the rate of protein synthesis in VSMC in response to Ang II.
Inhibition of IKKβ Reduces Ang II-Induced Protein Synthesis In Vivo
As the effect of ML120B on Ang II signaling events was identical in both cultured human and rat VSMC (Figure 3 and Figure II in the online-only Data Supplement), we were, therefore, well positioned to investigate the role of IKKβ in Ang II-induced hypertrophy in vivo using a previously reported rat model that allows the measurement of vascular protein synthesis. 24, 33 Although the dose of Ang II used in this protocol does not affect the mean blood pressure (Table) , it clearly induces vascular remodeling as observed by the enhanced rate of protein synthesis in rat aorta and rat mesenteric arteries ( Figure 5A and 5B) . It is worth mentioning that inhibition of IKKβ with ML120B resulted in an important reduction in the remodeling effect of the peptide without affecting the mean blood pressure, ruling out an indirect effect of this hemodynamic parameter. As expected, the use of the IKKβ inhibitor also reduced Ang II-induced VCAM-1 expression in aorta ( Figure 5C and 5D ). Taken together, these results demonstrate the physiological relevance of IKKβ requirement in both inflammatory and hypertrophic actions of Ang II.
Discussion
The vascular wall is an active organ, which consists of endothelial cells, VSMC, and fibroblasts. In the intact arterial media, VSMC and matrix are responsible for vessel wall contraction/relaxation, growth, development, remodeling, and repair, whereas abnormal growth of VSMC plays a major role in the development of vascular diseases, including hypertension and atherosclerosis. 3, 4 Deregulated production of the octapeptide Ang II mediates VSMC hypertrophy and inflammation. 2, 34 Therefore, understanding the signal transduction processes underlying Ang II-mediated cell growth is essential in identifying new therapeutic strategies to combat vascular diseases.
Previous studies have identified 2 major signaling cascades that are directly linked to Ang II-mediated protein synthesis in VSMC (Figure 6, right) . Selectively blocking MEK1 and MEK2 by PD98059 and consequently ERK1/2 and MAP kinase interacting serine/threonine kinase-1 reduced Ang II-induced protein synthesis in VSMC and rat aorta, 21, 33, 35 implicating the Ras-Raf-MEK1/2-ERK1/2-MAP kinase interacting serine/threonine kinase-1 signaling cascade in the increased rate of protein translation. Through the effect on TSC2, other studies also suggest that the ERK substrate mitogen-activated protein kinase-activated protein kinase p90 ribosomal S6 kinase is also required for full mTOR activation. 36, 37 The other major signaling cascade is the phosphatidylinositol 3-kinase-3-phosphoinositide dependent protein kinase 1-AKT module. Treatment of human SMC with phosphatidylinositol 3-kinase inhibitor wortmannin reduced both Ang II-mediated protein synthesis and dissociation of 4E-BP1 with eukaryotic translation initiation factor 4E, 26 whereas expression of a dominant-negative mutant of AKT in VSMC reduced Ang II-induced protein synthesis. 38 Interestingly, reactive oxygen species generation by Ang II also leads to the activation of AKT in a 3-phosphoinositide dependent protein kinase 1-and p38-dependent mechanism. 39 Therefore, in addition to the activation of MEK1/2-ERK1/2 modules, the phosphatidylinositol 3-kinase-AKT cascade is involved in Ang II-mediated protein synthesis in VSMC. Despite these detailed investigations, the molecular mechanisms by which Ang II mediates VSMC growth are not fully elucidated. In the present study, we examined the involvement of IKKβ in Ang II-induced VSMC growth. We have previously reported that Ang II induces tumor necrosis factor receptor-associated factor 6-transforming growth factor-β activated kinase-1 and ERK1/2-ribosomal S6 kinase intracellular pathways, independently and sequentially, which lead to T-loop phosphorylation of IKKβ. 5 This phosphorylation of IKKβ was observed as early as 15 seconds and plateaued within 5 to 10 minutes. Here, we demonstrate that on Ang II treatment, the detected phospho-signal of TSC1 at the IKKβ consensus site Ser511 increased after 5 minutes of stimulation, suggesting that IKKβ acts upstream of TSC1 ( Figure 1A ). Supporting this proposition is the fact that IKKβ was no longer able to phosphorylate a recombinant TSC1 lacking the IKKβ consensus site (Figure 2A ). In addition, reducing the expression level of IKKβ using short hairpin RNA or blocking its phosphotransferase activity using ML120B significantly reduced the phospho-signal of TSC1 on Ser511 (Figures 2C, 3A , and 3B and Figure II in the online-only Data Supplement). These results indicate that IKKβ phosphorylates TSC1 on Ser511 in response to Ang II in primary rat and human VSMC.
Ang II modulates the expression of proinflammatory molecules in the vessel wall, such as VCAM-1, which stimulates recruitment of mononuclear leucocytes into the vessel media. 40 In VSMC, the IKKβ inhibitor ML120B abrogated this Ang II-induced VCAM-1 expression ( Figure IB in the online-only Data Supplement). Interestingly, ML120B also dose-dependently reduced Ang II-induced autophosphorylation of mTOR ( Figure 3A and 3B) and downstream effectors of the mTORC1 pathway ( Figure 3C and 3D) . In fact, at the maximal concentration of 30 µmol/L, ML120B totally Values are mean±SEM. Ang II indicates angiotensin II; DBP, diastolic blood pressure; MBP, mean blood pressure; ML120B, N-(6-chloro-7-methoxy-9Hβ-carbolin-8-yl)-2 methylnicotinamide; n, number of rats per group in which hemodynamic measurements were made; and SBP, systolic blood pressure. (Ang II) . After binding to the Ang II type I receptor, a tumor necrosis factor receptor-associated factor 6 (TRAF6)-transforming growth factor-β activated kinase (TAK)1 complex leads to T-loop phosphorylation and activation of IKKβ, which is also under the control of a mitogen-activated protein kinase kinase (MEK)1/2-ERK1/2 pathway. 5 Activated IKKβ then phosphorylates p65 to induce an inflammatory response (not shown). In addition, our study reveals a novel signal transduction pathway whereby activated IKKβ phosphorylates and inhibits tuberous sclerosis (TSC) 1 to induce mammalian target of rapamycin (mTOR) activation, which leads to an increase in the rate of protein synthesis. Through their effect on TSC2, the MEK1/2-ERK1/2-p90RSK and phosphatidylinositol 3-kinase (PI3K)-3-phosphoinositide dependent protein kinase (PDK)1-V-Akt murine thymoma viral oncogene homolog (AKT)-p38 signaling modules are also involved in controlling the overall rate of protein synthesis. The protein kinase MAP kinase interacting serine/threonine kinase-1 (MNK1), which is activated by ERK1/2, is also implicated in cap-dependent translation. 4E-BP indicates eukaryotic initiation factor 4E-binding protein 1; MAPKAPK, mitogen-activated protein kinase-activated protein kinase; RHEB, Ras homolog enriched in brain; RSK, p90 ribosomal S6 kinase; and S6K, S6 kinase.
Figure 5.
Inhibition of IκB kinase-β (IKKβ) abrogates angiotensin II (Ang II)-induced protein synthesis in vivo. Two groups of rats were infused with Ang II for 26 hours, whereas 2 groups did not receive Ang II. A, After 22 hours, the animals that were infused with Ang II received the vehicle (n=9) or N-(6-chloro-7-methoxy-9H-β-carbolin-8-yl)-2 methylnicotinamide (ML120B; n=7) as an intravenous bolus dose of 0.25 mg/kg (equivalent to 10 µmol/L plasma concentration). In addition, after 22 hours, the animals that were not infused with Ang II also received the vehicle (n=6) or ML120B (n=4). The rate of protein synthesis was measured by [ 3 H]-leucine incorporation into the aorta. Data are displayed as mean±SEM. **P<0.005 vs Ang II. B, After 22 hours, the animals that were infused with Ang II received the vehicle (n=13) or ML120B (n=5) as an intravenous bolus dose of 0.25 mg/kg. In addition, after 22 hours, the animals that were not infused with Ang II also received the vehicle (n=12) or ML120B (n=4). The rate of protein synthesis was measured by [ 3 H]-leucine incorporation into the mesenteric arteries. Data are displayed as mean±SEM. *P<0.05 vs Ang II. C, Where indicated, rats were infused with Ang II for 6 hours. After 2 hours of stimulation, vehicle (n=3) or ML120B (n=3) was administrated as described in A. Control rats were sham operated. Protein lysates were prepared from aorta and subjected to immunoblot analysis. D, Densitometric analysis of vascular cell adhesion molecule 1 (VCAM-1) expression relative to β-actin expression presented in C. December 2013 mainly via an MEK1/2-ERK1/2-MAP kinase interacting serine/threonine kinase-1 independent pathway. The inhibitory behavior of the mutant of TSC1 lacking the IKKβ consensus site (TSC1 S511A) in human VSMC ( Figure 4C ) further demonstrates the importance of the IKKβ-TSC1 signaling module governing the hypertrophic effect of Ang II (Figure 6, left) . We would like to assert that this novel signaling module does not necessary lessen the contribution of previously characterized signaling cascades or second messenger molecules involved in the growth properties of Ang II. Rather, as observed in the generation of reactive oxygen species and protein kinases such as c-Src, which were previously shown to be part of upstream signaling cascades governing the activation of IKKβ, 41 we propose that specific vascular hypertrophic signaling pathways engaged by the Ang II type I receptor (eg, c-Src, generation of reactive oxygen species) might as well converge to the activation of IKKβ. Another scenario could also be considered, in which phosphorylation of TSC2 by the AKT and ERK1/2 pathways is involved but not sufficient to fully activate mTOR and increase the rate of protein synthesis in Ang II-treated cells. Notably, although TSC2 phosphorylation by ERK1/2 and AKT is proposed to inhibit its GTPase-activating protein function toward RHEB, 18, 19 phosphorylation of TSC1 on Ser511 was recently shown to be an upstream signaling event affecting its association with TSC2, altering TSC2 membrane localization and activation of the mTOR pathway. 14 In our in vivo studies, the IKKβ inhibitor ML120B was administered as an intravenous bolus to deliver a precise dose of ML120B into the vascular system. Because the pharmacokinetic profile of ML120B on intravenous administration was unknown, the dosage was selected from previous reports demonstrating that ML120B at a plasma concentration of 10 µmol/L is effective at inhibiting IKKβ-dependent NF-κB activation in vivo. 28 IKKβ inhibition at this concentration was confirmed by the observation that Ang II-mediated VCAM-1 expression was reduced in aorta ( Figure 5C and 5D). More importantly, IKKβ inhibition clearly reduced the rate of protein synthesis mediated by Ang II in both aorta and mesenteric vessels ( Figure 5A and 5B) . Taken together, the presented pharmacological and molecular data are most consistent with the involvement of IKKβ in the ability of Ang II to suppress the mTOR inhibitor TSC1, leading to activation of S6K1 and inhibition of 4E-BP1 and resulting in increased protein synthesis.
A previous study identified a link between the innate immune protein kinase IKKβ and TSC1 in cancer cells, which was proposed to be critical for inflammation-mediated tumor angiogenesis. 14 However, this study did not address whether this molecular link could become a potential target in cardiovascular diseases involving cellular processes associated with both growth and inflammatory events. Our study goes further to suggest that IKKβ is responsible for coupling the Ang II type I receptor not only to the activation of NF-κB transcription factors leading to a proinflammatory response 5, 6 but also to the direct activation of the mTORC1 pathway. We, therefore, propose that IKKβ could become an attractive target for drug development to treat pathological conditions, including hypertension and atherosclerosis.
